ALNY
Alnylam Pharmaceuticals, Inc.
$323.50
+1.91 (+0.59%)
At close · Jul 8
Market Cap
$41.48B
Shares
132,623,144
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$323.50
Open$318.50
Day$316.78–325.37
52W$273.11–495.55
Avg vol 30d1.2M
Short int5.4M · 4.1% float · 4.8d
Short vol60%
Last earningsApr 30, 2026
DataJan 2020–Jul 2026
Filing10-Q · Apr 30
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Bearish
Fundamentals
Excellent
Quant / Vol
High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−11%
below
Price vs 50-day avg
+9%
above
RSI (14)
69
neutral
MACD trend
Positive
52-week position
23%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+11%
trailing
6-month return
−13%
trailing
YTD return
−19%
this year
Relative strength
−20%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $297 › 200d $365 — 200d above 50d
Institutional flow
Distributing
34 of 790 funds reported for Jun 30 · net -11.8K sh shares
Insider flow
Distributing
Net -$1.1M over 90 days · 100% sells
Short interest
Rising
4.10% of float · ▲ +2.6% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
790 holders — mid 3-yr range
Squeeze score
69
elevated · 0–100
Fundamentals
Revenue growth
+23%
Y/Y
EPS growth
+207%
Y/Y
Free cash flow
$465.4M
Valuation
P/E 134.2
rich
Balance sheet
$981.6M
net cash
Quant / Vol
risk profile
Volatility
37%
annualized · 1-yr
Max drawdown
−43%
past year
ATR
3.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 6, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Apr 30, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance & track record
Latest guidance
· from the 8-K filed Apr 30, 2026
Combined Net Product Revenues
· 2026
Initiated
$4.9B – $5.3B
prior FY $3.71B
midpoint +37.3% Y/Y
Total TTR Net Product Revenues
· 2026
Lowered
$4.4B – $4.7B
prior FY $3.71B
midpoint +22.5% Y/Y
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−11%
Bearish
Price vs 50-day avg
+9%
Bullish
RSI (14)
69
Neutral
MACD trend
Positive
Bullish
52-week position
23%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $297 › 200d $365 — 200d above 50d
Institutional flow
Distributing
34 of 790 funds reported for Jun 30 · net -11.8K sh shares
Insider flow
Distributing
Net -$1.1M over 90 days · 100% sells
Short interest
Rising
4.10% of float · ▲ +2.6% MoM · 4.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
790 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $273
Now $324 · 23%
52-wk high $496
vs 200-day avg -11%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| AMVUTTRA % Change | 189% | Three Months Ended December 31 | — |
| AMVUTTRA % Change At CER | 187% | Three Months Ended December 31 | — |
| Total Rare net product revenues | 136,442K | Three Months Ended December 31 | — |
| Total Rare net product revenues % Change | 26% | Three Months Ended December 31 | — |
| Total Rare net product revenues % Change At CER | 23% | Three Months Ended December 31 | — |
| Total TTR net product revenues | 858,275K | Three Months Ended December 31 | — |
| Total TTR net product revenues % Change | 151% | Three Months Ended December 31 | — |
| Total TTR net product revenues % Change At CER | 149% | Three Months Ended December 31 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALNY
this stock
Alnylam Pharmaceuticals, Inc.
|
$41.48B | -18.6% | +22.9% | 134.2 | 4.1% |
|
ONC
BeOne Medicines Ltd.
|
$437.67B | -0.6% | +22179.2% | 890.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.01B | +9.9% | +46.2% | 29.5 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$70.03B | -14.0% | +20.8% | 16.3 | 3.2% |
|
ARGX
Argenx SE
|
$56.84B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALNY | +7.5% | +10.7% | -12.6% | +7.5% | -18.7% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +7.6% | +9.9% | -20.0% | +7.6% | -28.0% |
Key facts
CIK
1178670
CUSIP
02043Q107
13F (30d)
54 filings
32 filers
Visit website
Investor relations